anthrax news from FierceVaccines
News
VaxGen sells anthrax vaccine to its old rival
Reduced to a skeleton crew and a bleak outlook, South San Francisco-based VaxGen sold its experimental anthrax vaccine to its former chief rival, Emergent BioSolutions, for $2 million down and up to Read more...
PharmAthene bids for big anthrax vaccine contract
PharmAthene is making a bid to develop a next-gen anthrax vaccine that can qualify for a $400 million government contract. The small Maryland developer is paying up to $40 million for a pair of Read more...
Get more anthrax coverage at:
Paid Research Reports
- Pipeline Insight: Nosocomial Vaccines - Minefield or Goldmine?
- Drug Approval Trends at the FDA and EMEA: Process improvements, heightened scrutiny and industry response
- Biotech 2008 – life sciences industry report (online & print)
- Is there a market for alcoholism pharmacotherapies?
- New report provides Rheumatoid Arthritis market insight